Clinical Drug Trial Studies //

​

 

Currently Open

​

1.  VICTRIVA Vedolizumab 3043

• Moderate to Severe CD

• Vedolizumab (Entyvio) plus upadacitinib (Rinvoq) combo therapy vs vedolizumab monotherapy (vedolizumab and oral placebo) alone

• Treatment experienced or biologic naive patients welcome

• IV infusions of Entyvio every 8 weeks plus daily oral pill (Rinvoq or Placebo) for 12 weeks

• Total study treatment is 52 weeks

 

 

2. University of Alberta LFMT

• Moderate to Severe UC

• Patients who are staring Entyvio or Stelara, randomized 1:1 with Lyophilized Fecal Microbiota Transplantation (LFMT) or placebo

• Treatment experienced or biologic naive patients welcome

• Daily oral pill of LMFT or Placebo for 8 weeks as conjunction therapy to Entyvio or Stelara​

 

​

​

​

Coming Soon Drug Trials:

​

3. CHARGE (Guselkumab vs Risankizumab) Crohn’s Disease *October 2026*

• Moderate to Severe CD

• No placebo, patients receive 1:1 either Guselkumab (Tremfya) or Risankizumab (Skyrizi) for 52 weeks

• Previous Biologic Treatment experienced patients only

• Long Term Extension on Tremfya for another 2 years 

 

 

4. DUET-UC ENCORE (Guselkumab/Golimumab co-formulation) Ulcerative Colitis *November 2026*

• Moderate to Severe UC

• No placebo, patients receive 1:1 JNJ-4804 co-formulation drug or Guselkumab (Tremfya) for 48 weeks

• Must have failed/been intolerant to 2 or more biologics

• Long Term Extension on Tremfya for another 2 years 

​​

​

​

Currently Open Studies (non-drug):

​

1. IBD Registry

​

​​

​